Show simple item record

dc.contributor.authorPoor, Saghar Rabiei
dc.contributor.authorEttcheto, Miren
dc.contributor.authorCano, Amanda
dc.contributor.authorSánchez-López, Elena
dc.contributor.authorManzine, Patricia Regina
dc.contributor.authorOlloquequi, Jordi
dc.contributor.authorCamins, Antoni
dc.contributor.authorJavan, Mohammad
dc.date.accessioned2021-09-21T19:10:42Z
dc.date.available2021-09-21T19:10:42Z
dc.date.issued2021-09
dc.identifier10.3390/ph14090890
dc.identifier.issn14248247
dc.identifier.urihttps://hdl.handle.net/20.500.12728/9542
dc.description.abstractAlzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to “type 3 diabetes” and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models.es_ES
dc.language.isoenes_ES
dc.publisherMDPIes_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectAMP activated protein kinase AMPKes_ES
dc.subjectBeta amyloides_ES
dc.subjectDiabetes mellituses_ES
dc.subjectInsulin resistancees_ES
dc.subjectMetformines_ES
dc.subjectTau protein hyperphosphorylationes_ES
dc.titleMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatmentes_ES
dc.typeArticlees_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record